Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
aTyr Pharma is a clinical-stage biopharmaceutical company developing novel immunological therapeutics based on its proprietary tRNA synthetase biology platform. The company's lead candidate, efzofitimod, is in Phase 2/3 development for interstitial lung disease (ILD) associated with connective tissue disease, targeting a rare disease market with limited treatment options. With minimal revenue, high cash burn (~$30M annually), and a market cap of $100M, aTyr is a high-risk, binary-outcome biotech dependent on clinical trial success and capital markets access.
aTyr operates a classic clinical-stage biotech model with no current product sales. The company monetizes its tRNA synthetase platform through: (1) government grants (NIAID funding for COVID-19 research), (2) potential future partnerships for pipeline assets, and (3) eventual product commercialization if clinical trials succeed. The business model depends entirely on advancing efzofitimod through FDA approval for ILD-CTD, a rare disease indication that could command premium pricing ($100K+ annually per patient) given limited alternatives. With 5.93x current ratio and ~$30M cash runway, the company faces near-term financing needs. Value creation hinges on positive Phase 2b/3 data readouts and securing strategic partnerships or additional capital.
Clinical trial data readouts for efzofitimod in ILD-CTD (Phase 2b/3 EFZO-FIT study interim and final results)
FDA regulatory milestones - IND submissions, breakthrough therapy designation potential, meeting outcomes
Capital raises and financing announcements (dilution risk given $30M annual burn vs $100M market cap)
Partnership or licensing deals for efzofitimod or platform technology
Competitive developments in ILD-CTD treatment landscape (Boehringer Ingelheim's nintedanib, other emerging therapies)
Biotech sector sentiment and small-cap risk appetite (stock down 74% over 1-year, highly volatile)
Binary clinical trial risk - efzofitimod failure in Phase 2b/3 would likely render company value near-zero given single-asset focus and limited pipeline depth
Regulatory approval uncertainty - rare disease designations provide advantages but FDA standards remain rigorous; ILD-CTD endpoint validation challenges
Reimbursement risk - even with approval, payer coverage for rare disease therapies faces increasing scrutiny; need to demonstrate cost-effectiveness versus existing standards
Platform technology validation - tRNA synthetase biology is novel; scientific risk that mechanism doesn't translate across indications
Established competitors in ILD space - Boehringer Ingelheim's Ofev (nintedanib) has market presence; Roche's portfolio in fibrotic diseases
Emerging gene therapy and cell therapy approaches for autoimmune/fibrotic diseases could leapfrog small molecule approaches
Larger biotechs with deeper pipelines and resources can out-invest in clinical development and commercialization infrastructure
Patent expiration risk - need to maintain IP protection on tRNA synthetase platform and efzofitimod composition of matter
Imminent financing need - $30M annual cash burn versus $100M market cap implies dilutive capital raise likely within 12-18 months
Going concern risk if clinical trials fail and financing markets close - common for sub-$200M market cap biotechs
Negative equity risk - ROE of -100% reflects accumulated deficit; book value erosion continues until profitability
Minimal debt capacity - 0.15x D/E suggests limited ability to raise non-dilutive capital; venture debt requires clinical milestones
moderate - While drug demand is generally recession-resistant, aTyr's stock performance is highly sensitive to risk appetite for speculative biotech equities. Economic downturns reduce venture capital and public market financing availability, critical for pre-revenue biotechs. However, the company's focus on rare disease with unmet medical need provides some insulation from consumer spending cycles. Clinical trial execution is largely independent of GDP, but partnership valuations and exit multiples compress during recessions.
High sensitivity through multiple channels: (1) Valuation - clinical-stage biotechs are long-duration assets (cash flows 5+ years out) that decline significantly when discount rates rise; the 41.8% 3-month rally likely reflects recent rate stabilization expectations. (2) Financing costs - while current debt is minimal (0.15x D/E), future capital raises become more expensive in high-rate environments as investors demand higher returns. (3) Opportunity cost - rising risk-free rates make speculative biotech less attractive versus bonds. The stock's -80% decline over 6 months coincided with 2025's rate volatility.
Moderate - aTyr has minimal debt but depends critically on capital markets access for survival. Widening credit spreads signal risk-off sentiment that shuts down biotech IPO/follow-on markets and increases dilution in down-rounds. High-yield spreads serve as proxy for small-cap biotech financing conditions. The company's 5.93x current ratio provides temporary buffer, but sustained credit market stress could force unfavorable financing or strategic alternatives.
High-risk growth/speculative investors and biotech specialists seeking asymmetric binary outcomes. The -74% 1-year return and 42% 3-month rally exemplify extreme volatility typical of clinical-stage single-asset biotechs. Attracts: (1) venture-style investors comfortable with 90% loss/10x gain profiles, (2) event-driven funds playing clinical catalysts, (3) rare disease specialists who understand ILD-CTD market dynamics. NOT suitable for: income investors, risk-averse capital, or those requiring near-term profitability. The $100M market cap and -$30M annual FCF create existential financing risk.
high - Exhibits extreme volatility characteristic of sub-$200M market cap clinical-stage biotechs. The 6-month -80% drawdown followed by 3-month +42% rally demonstrates binary, catalyst-driven price action. Implied volatility likely exceeds 100% around data readouts. Low float and institutional ownership amplify moves. Beta to broader market likely 1.5-2.0x, but idiosyncratic clinical risk dominates systematic risk. Daily moves of 10-20% common around trial updates or sector rotation.
